stockrowVeracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
Follow VCYT
Alert me
Veracyte, Inc. (VCYT) Free cash flow
Veracyte, Inc.'s free cash flow for fiscal 2025 was $126.6M, up 98.5% from $63.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $161.9M. Over the past ten years it has ranged from −$37.0M (fiscal 2021) to $126.6M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 4 consecutive fiscal years. Veracyte, Inc. ranks 16th of 49 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $126.6M | 98.45% |
| FY2024 | $63.8M | 86.24% |
| FY2023 | $34.3M | — |
| FY2022 | −$1.0M | — |
| FY2021 | −$37.0M | — |
| FY2020 | −$12.5M | — |
| FY2019 | −$6.0M | — |
| FY2018 | −$15.4M | — |
| FY2017 | −$25.2M | — |
| FY2016 | −$32.2M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $37.9M | (11.74%) |
| Jun 2026 | $43.0M | 33.22% |
| Mar 2026 | $32.3M | (33.91%) |
| Dec 2025 | $48.8M | 16.29% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| VCYT Veracyte, Inc. | $161.9M |
| SHC Sotera Health Company compare | $135.4M |
| RDNT RadNet, Inc. compare | $74.4M |
| CDNA CareDx, Inc. compare | $59.8M |
| BLLN BillionToOne, Inc. compare | $33.9M |
| ADPT Adaptive Biotechnologies Corporation compare | −$8.8M |
| NEO NeoGenomics, Inc. compare | −$26.5M |
| WGS GeneDx Holdings Corp. compare | −$75.8M |
| GRAL GRAIL, Inc. compare | −$312.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on VCYT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement